首頁 > 市場調查報告書 > 醫療設備

傷口護理

市場調查報告書

商品編碼

1542953

全球傷口沖洗系統市場 - 2024-2031

Global Wound Irrigation System Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球傷口沖洗系統市場在2023年達到2.83億美元，預計到2031年將達到3.7295億美元，在2024-2031年預測期間複合年成長率為3.6%。

傷口沖洗系統被描述為溶液流過暴露的斷裂表面，以減少微生物定植，並去除明顯的異物顆粒和傷口滲出物。傷口沖洗（即在傷口閉合前沖洗傷口）旨在透過在部位閉合前清除手術區域的組織碎片、代謝廢物和組織滲出物來減少微生物負荷。當傷口沖洗正確時，可以加快癒合過程並降低併發症的風險。

唯一應該避免沖洗的傷口是那些正在流血的傷口。沖洗的主要優點是它有助於維持健康、濕潤的環境，有助於清潔、協助清創並改善傷口癒合過程。如果操作正確，可以減少傷口癒合的時間，並有助於減少疤痕。由於傷口沖洗相當簡單，因此無論您在哪裡，無論傷口位於何處，都可以輕鬆進行。

市場動態：

司機

慢性傷口的盛行率不斷增加

全球傷口沖洗系統市場的需求由多種因素所驅動。慢性傷口盛行率的上升推動了市場的成長。

此外，近年來外科手術的增加將推動該市場的需求。傷口沖洗系統在各種外科手術中扮演著非常重要的角色。 60歲以上老年人口的增加也是推動因素之一。該領域的技術進步也是傷口沖洗系統市場的主要促進因素之一。

慢性傷口是指那些沒有透過正常、有序和及時的修復過程進展的傷口。例如，根據 Wounds International 發布的一篇文章，根據一項估計，2023 年 12 月，7,700 萬名糖尿病患者中，25% 患有糖尿病足潰瘍。靜脈潰瘍是下肢慢性靜脈功能不全最嚴重、最令人衰弱的結果，佔下肢潰瘍的80%。印度慢性傷口的盛行率估計為每 1,000 人 4.5 人。

根據 facs.org 估計，已開發國家有 1% 到 2% 的人口一生中會遭受慢性傷口的困擾。據國際糖尿病聯盟稱，全球成年人口（20 - 79 歲）的 10.5% 估計患有糖尿病，而幾乎一半的人不知道自己患有糖尿病。

限制

先進傷口系統的高成本、發展中國家的可用性有限以及感染引起的危害等因素預計將阻礙市場的發展。

細分市場分析

全球傷口沖洗系統市場根據產品類型、應用、最終用戶和地區進行細分。

慢性傷口細分市場約佔全球傷口沖洗系統市佔率的44.1%

預計慢性傷口細分市場將在預測期內佔據最大的市場佔有率。在這一領域，政府監管的發展和慢性傷口沖洗技術的進步將推動該市場的發展。

由於全球人口慢性病的增加，近年來慢性傷口也增加。據 nih.gov 稱，腿部靜脈潰瘍是一項重大的臨床挑戰，它們是慢性靜脈功能不全 (CVI) 和靜脈高壓的結果。三個月的治愈率估計為 40%，一旦治愈，高達 80% 的患者會在 3 個月內復發。據通報，VLU 的盛行率約為 1.08%，發生率高達 1.33%。 VLU 的盛行率和發生率隨著年齡的成長而增加。

壓瘡是由於壓力或壓力與剪切力相結合造成的皮膚和/或皮下組織的局部損傷，通常位於骨突出處。據估計，美國約有 250 萬人因壓瘡住院。在英國，總治療費用的 4% 用於治療壓瘡。除了治療壓瘡的額外費用外，還有床位預約和住院產生的相關費用。這些潰瘍也導致護理人員工作量增加50%

市場地域佔有率

北美約佔全球傷口沖洗系統市佔率的46.3%

預計北美地區將在預測期內佔據最大的市場佔有率。慢性傷口發生率的上升、人們意識的增強以及政府在該地區分配的資金有助於推動市場的發展。

根據 facs.org 報導，據報道，在美國，慢性傷口影響著約 650 萬名患者。美國政府為傷口護理撥出了巨額資金。慢性傷口對社會帶來的經濟負擔是巨大的。在美國，醫療保健系統每年花費超過 250 億美元用於治療傷口相關併發症。慢性傷口影響著美國近 2.5% 人口的生活品質。這個比例在老年人中較大。這些傷口可能會導致一系列併發症和醫療費用。

北美地區的技術進步是其市場佔有率最大的原因之一。美國醫療保險和醫療補助服務中心提議修訂其當地承保決定，限制在美國醫療保險人群中使用皮膚替代移植物/細胞和/或基於組織的產品來治療糖尿病足潰瘍和靜脈性腿部潰瘍。

美國食品藥物管理局 (FDA) 重新將重點放在解決不癒合慢性傷口上，並概述了解決不癒合慢性傷口產品開發中已識別障礙的努力。新方法強調讓關鍵的傷口癒合利益相關者參與進來，包括學術界、專業協會、病患團體、報銷組織和產業。最後，最近的進展表明，由於屏障功能恢復方面的缺陷，根據目前 FDA 傷口閉合定義閉合的傷口可能仍保持功能開放，因此需要重新審視傷口閉合終點。

A Wound Irrigation system is described as the flow of a solution through an exposed fracture surface to reduce microbial colonization, to remove apparent foreign particles and wound exudates. Wound irrigation, that is washing out a wound before wound closure) aims to reduce the microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field before site closure. When wound irrigation is done correctly, it speeds up the healing process and reduces the risk of complications.

The only types of wounds that you should avoid irrigating are those that are actively bleeding. The primary advantages of irrigation are that it helps keep a healthy, moist environment that's conducive to cleaning, assists debridement, and improves the wound healing process. When done correctly, it reduces the amount of time a wound takes to heal and can help minimize scarring. Since wound irrigation is fairly straightforward, it's easy to perform anywhere you are, regardless of the location of your wound.

Market Dynamics: Drivers

Increasing prevalence of chronic wounds

The demand for the global wound irrigation system market is driven by multiple factors. The rising prevalence of chronic wounds propels the market growth.

Furthermore, the demand for this market will be fueled by the increase in surgical procedures in recent times. The wound irrigation system plays a very vital role in various surgical procedures. The increase in the population of older people who are 60 years and above is also one of the driving factors. Technological advancements in this field are also one of the major driving factors in the wound irrigation system market.

Chronic wounds are those that do not progress through a normal, orderly, and timely sequence of repair. For instance, according to an article posted by Wounds International, in December 2023, according to one estimate, out of 77 million individuals with diabetes, 25% develop a diabetic foot ulcer. Venous ulcers are the most severe and debilitating outcome of chronic venous insufficiency in the lower limbs, accounting for 80% of lower-extremity ulcerations. The prevalence of chronic wounds in India is estimated to be 4.5 per 1,000 people.

According to facs.org, it is estimated that 1 to 2 percent of the population in developed countries will suffer from a chronic wound in their lifetime. According to the International Diabetes Federation, 10.5% of the adult global population (20 - 79 years) is estimated to have diabetes with almost half of the people being unaware of it.

Restraints

Factors such as high cost associated with advanced wound systems, limited availability in developing countries, and hazards caused due to infection are expected to hamper the market.

Market Segment Analysis

The global wound irrigation system market is segmented based on product type, application, end-user, and region.

The segment chronic wounds accounted for approximately 44.1% of the global wound irrigation system market share

The chronic wounds segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and technological advancements for chronic wound irrigation would drive this market.

Due to the increase in chronic diseases in the global population, there has been an increase in chronic wounds in recent times. According to nih.gov, venous leg ulcers are a major clinical challenge they are the result of chronic venous insufficiency(CVI) and venous hypertension. Their three-month healing rate is estimated at 40 %and once healed up to 80% of patients develop a recurrence within 3 months. The prevalence of VLUs is reported around 1.08% and the incidence is up to 1.33%. The prevalence and incidence of VLU increase with age.

Pressure Ulcer is a localized injury to the skin and/or underlying tissue usually over a bony prominence, as a result of pressure, or pressure in combination with shear. It is estimated that about 2.5 million hospitalizations in the United States are due to pressure ulcers. In the UK, 4% of the total treatment costs are allocated for the treatment of pressure ulcers. In addition to the extra costs spent on the treatment of pressure ulcers, there are bed reservations and associated costs arising from hospitalization. These ulcers also cause the nursing staff an increase in workload by 50%

Market Geographical Share

North America accounted for approximately 46.3% of the global wound irrigation system market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of chronic wounds, growing awareness among people, and the funding allotted by the government in this region help to propel the market.

According to facs.org, In the United States, it is reported that chronic wounds affect approximately 6.5 million patients. The US government allotted a very hefty funding regarding wound care. The financial burden imposed by chronic wounds on society is substantial. In the United States, more than $25 billion is spent by the healthcare system on treating wound-related complications per year. Chronic wounds impact the quality of life of nearly 2.5% of the total population of the United States. This fraction is larger in the elderly. These wounds can lead to a range of complications and healthcare costs.

The technological advancements in the region of North America are one of the reasons for the largest market share. The U.S. Centers for Medicare and Medicaid Services had proposed a revision of its local coverage determination limiting the use of skin substitute grafts/cellular and/or tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the U.S. Medicare population.

The U.S. Food and Drug Administration (FDA) has renewed its focus on addressing non-healing chronic wounds and has outlined efforts to address identified barriers to product development for non-healing chronic wounds. The new approach emphasizes engaging key wound-healing stakeholders, including academia, professional associations, patient groups, reimbursement organizations, and industry. Finally, recent advances demonstrating that wounds closed by the current FDA definition of wound closure may remain functionally open because of deficiencies in the restoration of barrier function warrant revisiting the wound closure endpoint.

Market Segmentation

By Product Type

Manual Operated
Syringe Based
Spray Based
Nozzle Based
Battery Operated

By Application

Acute Wounds
Surgical Wounds
Traumatic Wounds
Burnt Wounds
Chronic Wounds
Diabetic foot Ulcers
Venous Ulcers
Pressure Ulcers
Others

By End-User

Hospitals
Ambulatory Surgical Centre
Homecare
Academic and Research Institutes
Others

By Region

North America
The U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the global wound irrigation system market include Zimmer Biomet, Stryker Corporation, Bionix Llc., Irrimax Corporation, Cooper Surgical Inc., Westmed Inc., Becton Dickson and Company, Essity Health & Medical, Centurion Service Group, and Hopkins Medical Products among others.

Key Developments

In June 2021, Irrimax Corporation, manufacturer of irrisept, announced new clearance from the U.S. Food and Drug Administration (FDA), making irrisept the only self-contained irrigation system for antimicrobial wound lavage in the U.S. market. Today, more than 2,000 U.S. hospitals are using the irrisept product totaling more than 2 million lifetime uses.
In April 2021, the FDA notified that Zimmer Biomet's single-step application wound irrigation solution, XPERIENCE No Rinse Antimicrobial Solution, has been cleared in the U.S. for immediate distribution. The device was originally submitted to the FDA as MIS Solution but is now being marketed as XPERIENCE.
In May 2021, BD (Becton, Dickinson, and Company) a leading global medical technology company, announced today the availability of BD Surgiphor(TM) Sterile Wound Irrigation System, the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution that mechanically loosens and removes wound debris.

Why Purchase the Report?

To visualize the global wound irrigation system market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global wound irrigation system market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Chronic Wounds
  - 4.1.1.2. Increase in Surgical Procedures
  - 4.1.1.3. Increase in population of older people
  - 4.1.1.4. Technological Advancements
4.2. Restraints
- 4.2.1. High Cost of Advanced Wound Irrigation Systems
- 4.2.2. Limited Accessibility in Developing Regions
4.3. Opportunity
4.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Manual Operated*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Battery Operated

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Acute Wounds *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chronic Wounds
7.4. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Homecare
8.5. Academic and Research Centers
8.6. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. UK
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Zimmer Biomet *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Striker Corporation
11.3. Bionix Llc.
11.4. Irrimax Corporation
11.5. Cooper Surgical Inc.
11.6. Westmed Inc.
11.7. Becton Dickson and Company
11.8. Essity Health & Medical
11.9. Centurion Service Group
11.10. Hopkins Medical Products (*LIST NOT EXHAUSTIVE)